Q32 Bio
Developing therapies targeting powerful regulators of innate and adaptive immunity to rebalance the immune system in severe autoimmune and inflammatory diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$300m (Public information from Nov 2023)
Cambridge Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
* | $46.0m | Series A | |
$60.0m | Series B | ||
* | $42.0m Valuation: $300m | Private Placement VC | |
N/A | N/A | IPO | |
* | $42.0m | Post IPO Equity | |
Total Funding | $148m |
Recent News about Q32 Bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Q32 Bio
EditACQUISITION by Q32 Bio Nov 2023